Voltage-gated L-type calcium channel (LTCC) (LTCC)

Voltage-gated L-type calcium channels (LTCCs), particularly the Cav1.2 subtype, are essential transmembrane proteins that regulate the entry of calcium ions into excitable cells such as vascular smooth muscle and cardiac myocytes (UniProt P15336). In the vascular system, these channels are the primary mediators of sympathetic nervous system-induced vasoconstriction; when activated by membrane depolarization—often triggered by alpha-adrenergic stimulation—they allow an influx of Ca2+ that initiates the contractile machinery (StatPearls, Calcium Channel Blockers). This process is a fundamental determinant of systemic vascular resistance and arterial blood pressure. Clinically, LTCCs are the primary targets for calcium channel blockers (CCBs), which are widely used to treat hypertension and angina by inducing vasodilation and reducing cardiac workload (PubMed, PMID: 29096778). These channels also play a vital role in cardiac conduction, particularly in the sinoatrial and atrioventricular nodes, making them targets for certain antiarrhythmic therapies. Dysregulation of LTCC activity is implicated in various cardiovascular pathologies, including chronic hypertension and hypertrophic cardiomyopathy. Therapeutic challenges include managing side effects like peripheral edema, which results from preferential dilation of precapillary arterioles, and potential bradycardia when using non-dihydropyridine agents (NIH, PubChem).

Other names

L-type calcium channelVoltage-dependent L-type calcium channelCav1.2Dihydropyridine receptorVoltage-operated calcium channelCalcium channel, voltage-dependent, L type, alpha 1C subunitCACNA1C

Inhibition of the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle cells by binding to the alpha-1 subunit of the L-type calcium channel, resulting in vasodilation and decreased myocardial contractility (StatPearls, Calcium Channel Blockers).